GlassScriptPhysician profile
John D Cheesborough
NPI 1396710380
$8,462.03
in general payments reported to CMS, 2019-2025
33 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $995 · 2021: $1,459 · 2022: $1,548 · 2023: $1,442 · 2024: $950 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,863.91 |
| Education | $365.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,843.01 | 2019-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $954.43 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $840.86 | 2019-2023 | |
| Abbvie INC. | $800.09 | 2019-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $478.89 | 2019-2024 | Cimzia, Bimzelx |
| Sun Pharmaceutical Industries INC. | $460.32 | 2019-2024 | Ilumya |
| Pfizer INC. | $448.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $398.87 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $375.25 | 2019-2024 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $366.32 | 2019-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $194.86 | 2023-2025 | Zoryve |
| Incyte Corporation | $173.51 | 2021-2023 | Opzelura |
| Genzyme Corporation | $171.18 | 2019-2025 | |
| Leo Pharma INC. | $167.61 | 2019-2025 | Adbry |
| Dermavant Sciences, INC. | $94.85 | 2023-2024 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $93.54 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $69.83 | 2019-2024 | |
| Celgene Corporation | $66.20 | 2019 | |
| Almirall LLC | $62.69 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $50.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.94 | 2022-2023 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.07 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $37.43 | 2019 | |
| Vyne Pharmaceuticals INC. | $34.52 | 2020-2021 | |
| Mission Pharmacal Company | $30.15 | 2019-2020 | |
| Epi Health, LLC | $25.35 | 2020 | |
| Organon LLC | $24.45 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $23.77 | 2023 | Ycanth |
| Botanix Sb INC | $19.27 | 2025 | Sofdra |
| Journey Medical Corporation | $18.86 | 2022 | |
| Dusa Pharmaceuticals, INC. | $15.97 | 2019 | |
| Dermira, INC. | $15.91 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cheesborough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.